New research suggests CCTA may provide salient preoperative insights into planning for percutaneous coronary intervention (PCI) while facilitating similar outcomes as intravascular ultrasound guidance for target-vessel failure.
|Articles|July 8, 2001
DRAXIS appoints new president
Richard Flanagan has been named president of DRAXIS’ radiopharmaceutical subsidiary, DRAXIMAGE. He has succeeded Ray Dore, who plans to retire in September but will continue to serve as a special advisor. Flanagan, who is currently executive vice
Advertisement
Richard Flanagan has been named president of DRAXIS’ radiopharmaceutical subsidiary, DRAXIMAGE. He has succeeded Ray Dore, who plans to retire in September but will continue to serve as a special advisor. Flanagan, who is currently executive vice president, has been with DRAXIMAGE since its founding in 1997.
Advertisement
Related to this article
Perspective and experience enable us to discern a reasonable explanation prior to boarding a rollercoaster of overreaction.
Catch up on the top radiology content of the past week.
Emerging CT research suggests that the plexus pancreaticus capitalis 2 (PPC2) pathway or a mass with stranding morphology may significantly increase mortality risk in patients with pancreatic cancer and extra-pancreatic nerve plexus invasion (EPNI).
Catch up on the most-well viewed radiology content in October 2026.
In the second of a two-part podcast episode, Kalpana Kanal, PhD, and Mahadevappa Mahesh, PhD, discussed the possible impact of new research showing significant declines in CT radiation dosing over the past decade, future research directions and the potential for indication-based diagnostic reference levels (DRLs) in the future.
Emerging research suggests that the benefits of photon-counting CT may be more pronounced in patients with obesity.
Catch up on the most well-viewed radiology video interviews from Diagnostic Imaging in September 2026.
Advertisement
Advertisement